Vor Biopharma Inc. (NYSE:VOR) Receives Average Rating of “Buy” from Analysts

Vor Biopharma Inc. (NYSE:VOR) has been assigned an average recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $11.36.

Several brokerages have commented on VOR. HC Wainwright reissued a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th. Robert W. Baird reduced their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. Finally, Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Vor Biopharma in a report on Monday, December 9th.

Vor Biopharma Trading Down 2.2 %

VOR opened at $0.87 on Tuesday. The firm has a market cap of $59.56 million, a price-to-earnings ratio of -0.53 and a beta of -0.37. The stock’s 50-day moving average price is $0.83 and its 200 day moving average price is $0.91. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $3.14.

Vor Biopharma (NYSE:VOR) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40). On average, research analysts forecast that Vor Biopharma will post -1.55 earnings per share for the current year.

Hedge Funds Weigh In On Vor Biopharma

Large investors have recently bought and sold shares of the stock. Rosalind Advisors Inc. acquired a new stake in shares of Vor Biopharma during the third quarter worth about $54,000. Exchange Traded Concepts LLC increased its position in Vor Biopharma by 40.8% during the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after buying an additional 48,017 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Vor Biopharma in the second quarter valued at approximately $53,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vor Biopharma in the second quarter valued at approximately $63,000. Finally, Hsbc Holdings PLC grew its position in shares of Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after acquiring an additional 31,333 shares during the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.